Kodiak Sciences Inc. (KOD) fair value analysis
Nasdaq · Updated 2026-10-19
KOD price how computed
Valuation status
No fair-value estimate yetKOD has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for KOD yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $85.75
- Sector
- Healthcare
- 12-month range
- $16.90–$99.87
- Market cap
- $5.39B
- From 52-week high
- -14.1%
- Shares outstanding
- 62.8M
- Rank in Healthcare by quality score
- #295 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Kodiak Sciences Inc. is a biopharmaceutical company that develops and commercializes therapies for retinal diseases, with a primary focus on age-related macular degeneration and diabetic retinopathy. The company operates in the United States and internationally through its operations and partnerships with healthcare providers and medical institutions.
KOD currently ranks #295 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $5.39B
- P/E (trailing)
- n/m
- EPS (TTM)
- $-4.19
- Debt / equity
- 1.57
- Shares outstanding
- 62.8M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 69 · neutral
- 50-day average
- $53.61
- 200-day average
- $38.83
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-12
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▼ miss (-8.2%)
2026-03 ▲ beat (+6.9%)
2025-12 ▼ miss (-3.0%)
2025-09 ▼ miss (-11.5%)
2025-06 ▲ beat (+1.9%)
2025-03 ▼ miss (-25.3%)
2024-12 ▲ beat (+2.8%)
2024-09 ▲ beat (+6.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 6 buy · 1 hold · 0 sell (7 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $122
- Target vs last price
- +42.3%
What our data shows for KOD
- Shares are trading in the upper third of their 12-month price range of $16.90–$99.87.
- The 14-day relative strength index sits at a neutral 69.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- KOD's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the KOD conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for KOD showed a shift this week as the RSI zone moved from overbought to neutral territory. The company's valuation verdict remains awaiting full valuation. These technical indicator changes reflect evolving price momentum patterns for the healthcare sector stock during the current period.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for KOD show a significant shift this week, with the RSI zone moving from oversold to overbought territory. The stock's valuation verdict remains awaiting full valuation as of the current assessment period.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — TickrTrends' derived indicators for KOD show that the 50/200-day trend state has shifted from mixed to uptrend this week. The stock, which operates in the healthcare sector, currently has a valuation verdict of awaiting full valuation, indicating that a complete assessment is pending.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is KOD stock undervalued?
TickrTrends has no fair-value estimate for KOD yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is KOD's TickrTrends verdict?
KOD is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does KOD compare to other Healthcare stocks?
KOD ranks #295 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is KOD overbought or oversold?
KOD's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does KOD report earnings next?
KOD's next earnings report is scheduled for 2026-11-12, per the published earnings calendar.
Does KOD usually beat earnings estimates?
Over its last 8 reported quarters KOD beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about KOD?
Of 7 analysts covering KOD, 6 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $122 (+42.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.